Growth-hormone axis · Peptide
CJC-1295
Also known as with/without DAC
A long-acting growth-hormone-releasing peptide, often paired with ipamorelin.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
Extends GHRH signaling for a longer GH pulse.
Benefits & effects studied
- Lean mass & recovery interest
- Often combined with ipamorelin
Research state
Early human data; not an approved drug.
Dosing & pharmacokinetics
DAC version weekly; non-DAC several times weekly (protocols). Half-life: DAC ~6–8 days; non-DAC ~30 min.
Dosing information is educational only. CJC-1295 decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described mid-2000s by ConjuChem Biotechnologies (Canada) Origin: Developed by Canadian biotech ConjuChem in the mid-2000s as a long-acting GHRH analog, originally aimed at obesity/wasting; its Drug Affinity Complex (DAC) lets it bind plasma albumin and extend its half-life to roughly eight days..
Molecular structure
A modified GHRH(1-29) peptide with four amino-acid substitutions plus a DAC (maleimido) group that covalently binds serum albumin.
Frequently asked questions
Is CJC-1295 FDA-approved?
Not FDA-approved; compoundable (removed from 503A Cat 2, Sep 2024) On Jevity's evidence scale, CJC-1295 is graded "Early / limited human data". Reclassification for compounding is not the same as FDA approval.
What is CJC-1295 used for?
A long-acting growth-hormone-releasing peptide, often paired with ipamorelin. Extends GHRH signaling for a longer GH pulse. Studied effects include: Lean mass & recovery interest; Often combined with ipamorelin. This is educational information, not a recommendation to use it.
Is CJC-1295 legal in the UAE?
UAE / DHA status: Prescription-only via a DHA-licensed clinic
Is CJC-1295 banned in sport?
WADA status: Prohibited at all times (GH axis)
What is CJC-1295's Jevity Score?
CJC-1295 has a Jevity Score of 45/100 — a proprietary composite of evidence strength (4/10), regulatory clarity (5/10) and supply verifiability (5/10). It reflects how established and legitimate the compound is, not a recommendation.
CJC-1295 is prescription-only or research-only. A licensed clinician must evaluate whether it's appropriate for you.
Book a consult →Related growth-hormone axis peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.